Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: Serious adverse events

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 3, 2012, Pages

  Cates, Christopher J ^a   Lasserson, Toby J ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b The Cochrane Collaboration   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FORMOTEROL; SALMETEROL; ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; SALBUTAMOL;

ADULT; AGE; ASTHMA; CAUSE OF DEATH; CHILD; CLINICAL OUTCOME; CONTROLLED CLINICAL TRIAL (TOPIC); DATA ANALYSIS; DISEASE SEVERITY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; MORTALITY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; CHRONIC DISEASE; META ANALYSIS;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHRONIC DISEASE; ETHANOLAMINES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861950024     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007695.pub3     Document Type: Review

References (83)

1. Condemi JJ. Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial. Clinical Therapeutics 2001; Vol. 23, issue 9:1529-41.
2. Everden P, Campbell M, Harnden C, McGoldrick H, Bodalia B, Manion V, et al.Eformoterol Turbohaler compared with salmeterol by dry powder inhaler in asthmatic children not controlled on inhaled corticosteroids. Pediatric Allergy and Immunology 2004; Vol. 15, issue 1:40-7.
3. Everden P, Lloyd A, Hutchinson J, Plumb J. Cost-effectiveness of eformoterol Turbohaler versus salmeterol Accuhaler in children with symptomatic asthma. Respiratory Medicine 2002; Vol. 96, issue 4:250-8.
4. Everden P, Reynia S, Lloyd AC, Hutchinson JL, Plumb JM. Economic evaluation of eformoterol compared with salmeterol in children aged 6-17 with symptomatic asthma in the UK: cost-effectiveness results of the FACT study. European Respiratory Journal 2001; Vol. 18, issue Suppl 33:122s.
5. Gabbay MB, Kane H, di Benedetto G. A comparison of formoterol and salmeterol dry powders in the treatment of nocturnal asthma [abstract]. European Respiratory Journal. Supplement. 1998; Vol. 12, issue Suppl 28:325S.
6. Rutten van Molken MP, van Doorslaer EK, Till MD. Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma. Pharmacoeconomics 1998; Vol. 14, issue 6:671-84.
7. Sanguinetti CM, Duce F, Quebe Fehling E, Della Cioppa G, Di Benedetto G. A 6-month open comparison between formoterol and salmeterol dry powders in patients with reversible obstructive airway disease. European Respiratory Journal 1997; Vol. 10, issue Suppl 25:241S.
8. Vervloet D, Ekstrom T, Pela R, Duce Gracia F, Kopp C, Silvert BD, et al.A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Respiratory Medicine 1998; Vol. 92, issue 6:836-42.
9. Brambilla C, Le Gros V, Bourdeix I. Formoterol 12 mug BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study. Clinical Therapeutics 2003; Vol. 25, issue 7:2022-36.
10. Campbell LM, Anderson TJ, Parashchak MR, Burke CM, Watson SA, Turbitt ML. A comparison of the efficacy of long-acting beta 2-agonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics. [Force Research Group corrected and republished with original paging, article originally printed in Respiratory Medicine 1999 Apr;934:236-44]. Respiratory Medicine 1999; Vol. 93, issue 7:236-44.
11. Eryonucu B, Uzun K, Guler N, Tuncer M, Sezgi C. Comparison of the short-term effects of salmeterol and formoterol on heart rate variability in adult asthmatic patients. Chest 2005; Vol. 128, issue 3:1136-9.
12. Heijerman HG, Dekker FW, Rammeloo RH, Roldaan AC, Sinninghe HE. Similar efficacy of formoterol via turbuhaler and salmeterol via diskhaler in the treatment of asthma. European Respiratory Society; 1999 Oct 9-13; Madrid, Spain 1999:[P2209].
13. Larsson S. Long-term studies on long-acting sympathomimetics. Lung 1990; Vol. 168, issue Suppl:22-4.
14. Lemaigre V, Van den Bergh O, Smets A, De Peuter S, Verleden GM. Effects of long-acting bronchodilators and placebo on histamine-induced asthma symptoms and mild bronchus obstruction. Respiratory Medicine 2006; Vol. 100, issue 2:348-53.
15. Novartis. A 12-month multicenter, randomized, double-blind, double-dummy trial to examine the long-term tolerability of formoterol 10μg via the multiple dose dry powder inhaler (MDDPI), both as twice daily maintenance therapy and as on-demand use in addition to maintenance in patients with persistent asthma. http://pharma.us.novartis.com/ 2005.
16. Pohunek P, Matulka M, Rybnicek O, Kopriva F, Honomichlova H, Svobodova T. Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma. Pediatric Allergy and Immunology 2004; Vol. 15:32-9.
17. Sill V, Bartuschka B, Villiger B, Ortland C, Domej W. Changes in specific airway resistance after powder inhalation of formoterol or salmeterol in moderate bronchial asthma. Pneumologie 1999; Vol. 53, issue 1:4-9.
18. van der Woude HJ, Postma DS, Politiek MJ, Winter TH, Aalbers R. Relief of dyspnoea by beta2-agonists after methacholine-induced bronchoconstriction. Respiratory Medicine 2004; Vol. 98, issue 9:816-20.
19. van Veen A, Weller FR, Wierenga EA, Jansen HM, Jonkers RE. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists. Pulmonary Pharmacology and Therapeutics 2003; Vol. 16, issue 3:153-61.
20. Verini M, Verrotti A, Greco R, Chiarelli F. Comparison of the bronchodilator effect of inhaled short- and long-acting beta2-agonists in children with bronchial asthma. A randomised trial. Clinical Drug Investigation 1998; Vol. 16, issue 1:19-24.
21. Von Berg A, Papageorgiou Saxoni F, Wille S, Carrillo T, Kattamis C, Helms PJ. Efficacy and tolerability of formoterol Turbuhaler in children. International Journal of Clinical Practice 2003; Vol. 57:852-6.
22. Altman DG, Bland JM. Statistics notes: interaction revisited: the difference between two estimates. BMJ 2003;326(7382):219.
23. Anderson GP. Current issues with beta(2)-adrenoceptor agonists - pharmacology and molecular and cellular mechanisms. Clinical Reviews in Allergy and Immunology 2006; Vol. 31, issue 2-3:119-30.
24. Arnold JMO, O'Connor PC, Riddell JG, Harron DWG, Shanks RG, McDevitt DG. Effects of the beta-2-adrenoceptor antagonist ici-118, 551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. British Journal of Clinical Pharmacology 1985; Vol. 19, issue 5:619-30.
25. Barnes PJ. Beta-adrenoceptors on smooth-muscle, nerves and inflammatory cells. Life Sciences 1993; Vol. 52, issue 26:2101-9.
26. Barnes PJ. Beta-adrenergic receptors and their regulation. American Journal of Respiratory and Critical Care Medicine 1995; Vol. 152, issue 3:838-60.
27. Bennett JA, Smyth ET, Pavord ID, Wilding PJ, Tattersfield AE. Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax 1994; Vol. 49, issue 8:771-4.
28. Bijl-Hofland ID, Cloosterman SG, Folgering HT, van den Elshout FJ, van Weel C, van Schayck CP. Inhaled corticosteroids, combined with long-acting beta(2)-agonists, improve the perception of bronchoconstriction in asthma. American Journal of Respiratory and Critical Care Medicine 2001; Vol. 164, issue 5:764-9.
29. Blauw GJ, Westendorp RGJ. Asthma deaths in New Zealand - whodunnit. The Lancet 1995;345:2-3.
30. Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta-2-receptor stimulation by circulating epinephrine. New England Journal of Medicine 1983; Vol. 309, issue 23:1414-9.
31. Burgess CD, Windom HH, Pearce N, Marshall S, Beasley R, Siebers RWL, et al.Lack of evidence for beta-2 receptor selectivity - a study of metaproterenol, fenoterol, isoproterenol, and epinephrine in patients with asthma. American Review of Respiratory Disease 1991; Vol. 143, issue 2:444-6.
32. Burggraaf J, Westendorp RGJ, in't Veen J, Schoemaker RC, Sterk PJ, Cohen AF, et al.Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients. Thorax 2001; Vol. 56, issue 7:567-9.
33. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD006363.pub2].
34. Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD006923.pub2].
35. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD006924.pub2].
36. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD006922.pub2].
37. Cates CJ, Lasserson TJ. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD007694.pub2].
38. Cockcroft DW, McParland CP, Britto SA, Swystun VA, Rutherford BC. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993; Vol. 342, issue 8875:833-7.
39. Collins JM, McDevitt DG, Shanks RG, Swanton JG. Cardio-toxicity of isoprenaline during hypoxia. British Journal of Pharmacology 1969; Vol. 36, issue 1:35-7.
40. Crane J, Pearce N, Flatt A, Burgess C, Jackson R, Kwong T, et al.Prescribed fenoterol and death from asthma in New Zealand, 1981-83 - case-control study. Lancet 1989; Vol. 1, issue 8644:917-22.
41. Ducharme FM, Lasserson TJ, Cates CJ. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD003137.pub3].
42. Giembycz MA, Newton R. Beyond the dogma: novel ß2-adrenoceptor signalling in the airways. European Respiratory Journal 2006;27(6):1286-306.
43. Grainger J, Woodman K, Pearce N, Crane J, Burgess C, Keane A, et al.Prescribed fenoterol and death from asthma in New Zealand, 1981-7 - a further case-control study. Thorax 1991; Vol. 46, issue 2:105-11.
44. Greenstone IR, Ni Chroinin M, Masse V, Danish A, Magdalinos H, Zhang X, et al.Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD005533].
45. Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 2000; Vol. 55, issue 8:650-6.
46. Hall JA, Petch MC, Brown MJ. Intracoronary injections of salbutamol demonstrate the presence of functional beta-2-adrenoceptors in the human-heart. Circulation Research 1989; Vol. 65, issue 3:546-53.
47. Hanania NA, Sharfkhaneh A, Barber R, Dickey BF. Beta-agonist intrinsic efficacy - measurement and clinical significance. American Journal of Respiratory and Critical Care Medicine 2002; Vol. 165, issue 10:1353-8.
48. Hanania NA, Moore RH, Zimmerman JL, Miller CT, Bag R, Sharafkhaneh A, et al.The role of intrinsic efficacy in determining response to beta(2)-agonist in acute severe asthma. Respiratory Medicine 2007; Vol. 101, issue 5:1007-14.
49. Hancox RJ, Aldridge RE, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, et al.Tolerance to beta-agonists during acute bronchoconstriction. European Respiratory Journal 1999; Vol. 14, issue 2:283-7.
50. Hancox RJ. Concluding remarks: can we explain the association of beta-agonists with asthma mortality? A hypothesis. Clinical Reviews in Allergy and Immunology 2006; Vol. 31, issue 2-3:279-88. [1080-0549: (Print)].
51. Haney S, Hancox RJ. Recovery from bronchoconstriction and bronchodilator tolerance. Clinical Reviews in Allergy and Immunology 2006; Vol. 31, issue 2-3:181-96.
52. Harvey JE, Tattersfield AE. Airway response to salbutamol - effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects. Thorax 1982; Vol. 37, issue 4:280-7.
53. Jaeschke R, O'Byrne PM, Nair P, Mejza F, Lesniak W, Brozek J, et al.The safety of formoterol among patients with asthma using inhaled corticosteroids. Systematic review and meta-analysis. Polskie Archiwum Medycyny Wewnetrznej 2008; Vol. 118, issue 11:627-35.
54. Jaeschke R, O'Byrne PM, Mejza F, Nair P, Lesniak W, Brozek J, et al.The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and meta-analysis. American Journal of Respiratory and Critical Care Medicine 2008; Vol. 178, issue 10:1009-16.
55. Jones SL, Cowan JO, Flannery EM, Hancox RJ, Herbison GP, Taylor DR. Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. European Respiratory Journal 2001; Vol. 17, issue 3:368-73.
56. Lee DKC, Jackson CM, Currie GP, Cockburn WJ, Lipworth BJ. Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. British Journal of Clinical Pharmacology 2003; Vol. 56, issue 5:494-500.
57. Lipworth BJ, Struthers AD, McDevitt DG. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high-dose inhaled salbutamol in asthmatics. American Review of Respiratory Disease 1989; Vol. 140, issue 3:586-92.
58. Lipworth BJ, McDevitt DG. Inhaled beta-2-adrenoceptor agonists in asthma - help or hindrance. British Journal of Clinical Pharmacology 1992; Vol. 33, issue 2:129-38.
59. Lipworth BJ. Airway subsensitivity with long-acting beta 2-agonists: is there cause for concern?. Drug Safety 1997;16(5):295-308.
60. Lipworth BJ, Aziz I. Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. Chest 2000; Vol. 117, issue 1:156-62.
61. McDevitt DG, Shanks RG, Swanton JG. Further observations on cardiotoxicity of isoprenaline during hypoxia. British Journal of Pharmacology 1974; Vol. 50, issue 3:335-44.
62. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. American Journal of Respiratory and Critical Care Medicine 1998; Vol. 158, issue 3:924-30.
63. Morrison KJ, Gao Y, Vanhoutte PM. Beta-adrenoceptors and the epithelial layer in airways. Life Sciences 1993; Vol. 52, issue 26:2123-30.
64. Nelson HS, Raine D, Doner HC, Posey WC. Subsensitivity to bronchodilator action of albuterol produced by chronic administration. American Review of Respiratory Disease 1977; Vol. 116, issue 5:871-8.
65. Ni Chroinin M, Greenstone IR, Danish A, Magdolinos H, Masse V, Zhang X, et al.Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD005535].
66. Ni Chroinin M, Greenstone IR, Ducharme FM. Addition of long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD005307].
67. Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. American Journal of Respiratory and Critical Care Medicine 1999; Vol. 160, issue 1:244-9.
68. Pearce N, Grainger J, Atkinson M, Crane J, Burgess C, Culling C, et al.Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 1990; Vol. 45, issue 3:170-5.
69. Pearce N. Adverse Reactions: the Fenoterol Story. 1. Auckland: Auckland University Press, 2007:215. [ISBN: 9781869403744].
70. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
71. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Annals of Internal Medicine 2006;144(12):904-12.
72. Sears M, Rea H, Rothwell R, O'Donnell T, Holst P, Gillies A, et al.Asthma mortality: comparison between New Zealand and England. British Medical Journal 1986;293(6558):1342-5.
73. Sears MR, Taylor DR, Print CG, Lake DC, Li QQ, Flannery EM, et al.Regular inhaled beta-agonist treatment in bronchial-asthma. Lancet 1990; Vol. 336, issue 8728:1391-6.
74. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, the SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26.
75. Speizer FE, Doll R, Heaf P. Observations on recent increase in mortality from asthma. British Medical Journal 1968; Vol. 1, issue 5588:335-7.
76. van der Woude HJ, Winter TH, Aalbers R. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta(2) agonists. Thorax 2001; Vol. 56, issue 7:529-35.
77. van Noord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FPV. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. European Respiratory Journal 1996; Vol. 9, issue 8:1684-8.
78. Walters EH, Walters JAE, Gibson PW. Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD003901].
79. Walters EH, Gibson PG, Lasserson TJ, Walters JAE. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD001385.pub2].
80. Weber RW, Smith JA, Nelson HS. Aerosolized terbutaline in asthmatics - development of subsensitivity with long-term administration. Journal of Allergy and Clinical Immunology 1982; Vol. 70, issue 6:417-22.
81. Wilson JD, Sutherland DC, Thomas AC. Has the change to beta-agonists combined with oral theophylline increased cases of fatal asthma. Lancet 1981; Vol. 1, issue 8232:1235-7.
82. Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE. Bronchodilator, cardiovascular, and hypokalemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990; Vol. 336, issue 8728:1396-9.
83. Yates DH, Kharitonov SA, Barnes PJ. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta(2)-agonist. American Journal of Respiratory and Critical Care Medicine 1996; Vol. 154, issue 6:1603-7.